ArticleResearch and practice in thrombosis and haemostasis2021
2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines.
Article in Research and practice in thrombosis and haemostasis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- Pseudothrombocytopenia and other conditions associated with spuriously low platelet counts.Haematologica · 2025Review
- Rewriting the script: gene therapy and genome editing for von Willebrand Disease.Frontiers in genome editing · 2025Review
- Letter in response to Othman & Favaloro "Comparison of two ways of performing ristocetin-induced platelet agglutination (RIPA) mixing study for diagnosis of type 2B VWD".Research and practice in thrombosis and haemostasis · 2023Article
- Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources.Research and practice in thrombosis and haemostasis · 2023Review
- Comparison of 2 ways of performing ristocetin-induced platelet agglutination mixing study for diagnosis of type 2B von Willebrand disease. Response to the publication of Soleimani et al.Research and practice in thrombosis and haemostasis · 2023Article
- Laboratory Testing for von Willebrand Disease Using a Composite Rapid 3-Test Chemiluminescence-Based von Willebrand Factor Assay Panel.Methods in molecular biology (Clifton, N.J.) · 2023Article
- 2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines.Research and practice in thrombosis and haemostasis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent American Society of Hematology/ISTH/National Hemophilia Foundation/World Federation of Hemophilia 2021 guidelines on the diagnosis of von Willebrand disease (VWD) is an outstanding effort to unify the diagnosis of VWD. However, as mentioned in the guidelines, there are limitations due to the low certainty in the evidence identified for most questions. The panel encouraged critical review of the guidelines. Compared to other subtypes, there is considerable complexity with diagnosis of type 2B VWD, a type that results from a gain-of-function mutation in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.